ChemoCentryx Stock News

ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q3 2021 Results - Earnings Call Transcript

ChemoCentryx (CCXI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

MOUNTAIN VIEW, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2021 financial results will be released after market close

ChemoCentryx (CCXI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

These stocks are expected to put up big gains in a short amount of time.

The stock surged after obtaining FDA approval for avacopan.

These two small drugmakers are poised for a long-winded growth spurt.

There's an old saying on Wall Street that "gaps refill." It's true and it may be about to happen to shares of ChemoCentryx, Inc. (NASDAQ:CCXI).

The stock price of ChemoCentryx Inc (NASDAQ: CCXI) increased by over 9% during intraday trading today. This is why it happened.

Appointment Brings More than 20 Years of Drug Development Experience as Company Launches First Product

Investors are excited about the biotech's game-changing new drug.

On Friday, ChemoCentryx Inc. (NASDAQ:CCXI) shares spiked nearly 70% after announcing the Food and Drug Administration (FDA) had approved avacopan for the treatment of ANCA vasculitis. Avacopan is an o

The broader market was mixed on Friday.

The stock price of ChemoCentryx Inc (NASDAQ: CCXI) increased by over 88% during intraday trading today. This is why it happened.

ChemoCentryx Inc (NASDAQ: CCXI) shareholders had every reason to be happy about on Friday morning. The shares of the group traded higher on Friday morning, thanks to the announcement made by the group